Literature DB >> 11118966

Antidote availability in Quebec hospital pharmacies: impact of N-acetylcysteine and naloxone consumption.

B Bailey1, J F Bussières.   

Abstract

OBJECTIVES: To study the availability of 13 specific antidotes in hospitals and correlate the availability of those antidotes to the number of poisonings seen in hospitals using N-acetylcysteine and naloxone consumption as a surrogate.
METHODS: Pharmacy directors of hospitals with an emergency department were surveyed for number of adequately stocked antidotes (N-acetylcysteine, ethanol, cyanide antidote kit or hydroxycobalamine, deferoxamine, digoxin-immune FAB, dimercaprol, flumazenil, glucagon, methylene blue, naloxone, physostigmine, pralidoxime and pyridoxine).
RESULTS: Data were obtained from 96 of 112 (86%) of the pharmacies surveyed. Number of adequately stocked antidotes per hospital ranged from zero to nine of 13. There was a correlation between all hospital characteristics evaluated and the number of adequately stocked antidotes (P<0.05). Correlations between the number of adequately stocked antidotes and the amount of N-acetylcysteine and naloxone consumed were significant (rs=0.58, P<0.001; r(s)=0.53, P<0.001). The amount of N-acetylcysteine consumed, the number of annual visits to the emergency department and the number of hours of pharmacy coverage on weekends independently predicted the presence of adequately stocked antidotes.
CONCLUSIONS: Larger hospitals are more likely to have adequate stocks of antidotes. Adequate stocking of antidotes is significantly correlated with the amount of N-acetyl- cysteine and naloxone consumed. This suggests that hospitals more likely to see serious acetaminophen and opiate poisonings are more likely to maintain adequate stocks of antidotes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118966

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  2 in total

1.  The cost of maintaining adequate antidote supplies.

Authors:  B Bailey; J F Bussières
Journal:  CMAJ       Date:  2001-11-27       Impact factor: 8.262

2.  Path to the Canadian Antidote Registry.

Authors:  Pierre-André Dubé
Journal:  Can J Hosp Pharm       Date:  2018-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.